Skip to main content
logo
SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.790
+0.220 (6.16%)
At close: Aug 3, 2026, 4:00 PM EDT
3.840
+0.050 (1.32%)
After-hours: Aug 3, 2026, 4:56 PM EDT

SAB Biotherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--1.322.2423.960.88
Revenue Growth
---40.94%-90.63%-60.73%10.21%
Gross Profit
--1.322.2423.960.88
Operating Income
-58.18-48.95-42.91-38.08-28.92-13.39
Net Income
-0.413.27-34.11-42.19-18.74-17.14
Earnings Per Share
-2.11-0.79-3.68-7.64-4.31-6.30
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
107.3996.5920.7656.5715.0539.55
Total Debt
6.175.954.675.915.934.75
Net Cash (Debt)
101.2290.6416.0950.669.1234.79
Net Cash Growth
1568.24%463.28%-68.23%455.59%-73.79%305.50%
Net Cash Per Share
1.371.481.749.172.0912.73

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-51.25-44.78-34.29-25.12-23.461.99
Capital Expenditures
--0.93-0.34-0.2-2.17-10.94
Free Cash Flow
-51.25-45.71-34.63-25.32-25.63-8.96
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--100.00%100.00%100.00%100.00%
Operating Margin
---3244.87%-1700.56%-120.97%-22.00%
Pretax Margin
---2579.03%-1884.50%-78.29%-28.16%
Profit Margin
---2579.03%-1884.50%-78.19%-28.16%
FCF Margin
---2618.65%-1130.71%-107.20%-14.71%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
--26.6228.351.245.58